glucagon-like-immunoreactivity

prefer explicit peptides, this general immunoreactivity term has declining use; kept for historical purposes; peptides which have an immunodeterminant similar to the 2-23 region of glucagon, but not immunodeterminant similar to glucagon; do not confuse with Gli1 protein which is a transcription factor

Also Known As:

Networked: 31 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 01/01/1977 - "The response of glucagon-like immunoreactivity to reactive hypoglycemia." 06/01/1981 - "Exaggerated response of plasma glucagon-like immunoreactivity (GLI) to oral glucose in patients with reactive hypoglycemia." 03/01/1989 - "Previous studies demonstrated that insulin-induced hypoglycemia enhances glicentin secretion in piglets and prompted us to investigate the response of glucagon-like immunoreactivity (GLI) to hypoglycemia in dogs. " 06/01/1981 - "In order to study the pathogenesis of reactive hypoglycemia, the responses of plasma glucose, IRI, glucagon immunoreactivity (GI) and total glucagon-like immunoreactivity (GLI) to 100 g oral glucose load were investigated in twenty-six patients of normal weight with reactive hypoglycemia. " 02/01/1981 - "Changes in plasma C-terminal glucagon-like immunoreactivity (C-GLI) and C-peptide immunoreactivity (CPR) following hypoglycemia were commensurate with blood glucose levels and were not significantly influenced by islet denervation. "
2.	Neoplasms (Cancer) 07/01/1982 - "PP-like and glucagon-like immunoreactivity were observed in two endocrine pancreatic tumors. " 02/01/1985 - "In the present study we characterized and compared the different molecular forms of glucagon-like immunoreactivity in extracts of peripheral plasma and hepatic metastases of a patient with pancreatic alpha-cell tumor. " 09/01/1985 - "Immunocytochemistry revealed that the distribution of GLP-1-(1-19) immunoreactivity followed that of glucagon-like immunoreactivity in the normal human pancreas and in two human glucagon-secreting pancreatic tumors. " 10/15/1987 - "After a review of the literature on this subject, this case is believed to be highly unusual in several respects: (1) despite their small size, these tumors resulted in multiple metastases to the regional lymph nodes; (2) both primary tumors and metastases were extensively and strongly argentaffin; and (3) most tumors and metastases contained, when investigated by immunocytochemistry, several biologically active substances such as serotonin, somatostatin, and glucagon-like immunoreactivity." 04/15/1990 - "Characterization of plasma and tumor glucagon-like immunoreactivity (GLI) by high-performance liquid chromatography and radioimmunoassay for GLI showed different chromatographic profiles, with glucagon the major molecular form in the tumor, and glicentin and oxyntomodulin predominating in plasma. "
3.	Neoplasm Metastasis (Metastasis) 02/01/1985 - "In the present study we characterized and compared the different molecular forms of glucagon-like immunoreactivity in extracts of peripheral plasma and hepatic metastases of a patient with pancreatic alpha-cell tumor. " 02/01/1985 - "Differences in molecular heterogeneity of glucagon-like immunoreactivity in plasma and liver metastases of a patient with alpha-cell tumor." 02/01/1985 - "The results clearly demonstrated that both plasma and glucagon-like immunoreactivity extracted from hepatic metastases were heterogeneous and comprised species corresponding not only to "true" glucagon but also to higher mol wt forms. " 02/01/1985 - "Total plasma glucagon-like immunoreactivity prior to surgery was 26.64 nmol/l and consisted of four peaks of immunoreactivity of apparent 9,000 mol wt, 5,800-5,400 mol wt, and 4,000 mol wt. Total glucagon-like immunoreactivity extracted from the hepatic metastasis was 47.41 nmol/g wet weight and eluted as two major peaks of immunoreactivity as follows: peak I, mol wt 3,800, corresponding to "true" 3,500 mol wt glucagon; peak II, mol wt 1,400, probably consisted of glucagon degradation products. " 10/15/1987 - "After a review of the literature on this subject, this case is believed to be highly unusual in several respects: (1) despite their small size, these tumors resulted in multiple metastases to the regional lymph nodes; (2) both primary tumors and metastases were extensively and strongly argentaffin; and (3) most tumors and metastases contained, when investigated by immunocytochemistry, several biologically active substances such as serotonin, somatostatin, and glucagon-like immunoreactivity."
4.	Septic Shock (Toxic Shock Syndrome) 01/01/1985 - "The purpose of the present study was to determine the importance of gastrointestinal-derived glucagon (glucagon-like immunoreactivity; GLI) during endotoxin shock. "
5.	Chronic Pancreatitis 06/01/1971 - "Pancreatic-glucagon-like immunoreactivity after intravenous insulin in normals and chronic-pancreatitis patients." 06/11/1977 - "Unmodified synthetic somatostatin, given as a 200-microgram intravenous bolus, plus 200 microgram infused over 3 hours, had no effect on basal plasma insulin and pancreatic glucagon-like immunoreactivity (GLI) levels, both in controls and in patients with chronic pancreatitis. " 12/01/1977 - "Oral glucose administration caused an exaggerated release of cross-reacting gastrointestinal glucagon-like immunoreactivity (GLI) and a slight early rise in immunoreactive glucagon (IRG) concentration in patients with chronic pancreatitis, who have impaired insulin release. " 05/01/1976 - "The plasma gastric inhibitory polypeptide (GIP), pancreatic glucagon-like immunoreactivity (PGLI), and gut glucagon-like immunoreactivity (GGLI) responses to oral glucose have been measured in five patients with chronic pancreatitis (with diabetic glucose tolerance tests) and in matched nondiabetic controls. " 09/01/1975 - "over forty minutes) on plasma pancreatic glucagon-like immunoreactivity (PGLI), serum insulin, and blood glucose were studied in six patients with chronic pancreatitis and six matched controls.asal PGLI levels were significantly higher in the patients, despite higher fasting glucose concentrations. "

Related Drugs and Biologics

1.	Glucagon (Glukagon)
2.	Insulin (Novolin)
3.	Glucose (Dextrose)
4.	Glicentin
5.	Blood Glucose (Blood Sugar)
6.	Substance P
7.	Somatostatin (Somatotropin Release-Inhibiting Factor)
8.	Pancreatic Polypeptide (Pancreatic Polypeptide (PP))
9.	Gastrins
10.	Glucagon-Like Peptides (Enteroglucagon)

Related Therapies and Procedures

1.	Cardiopulmonary Resuscitation (CPR)
2.	Intravenous Infusions
3.	Denervation